By Justin Petrone

Kinexus, a 10-year-old proteomics company based in Vancouver, BC, later this month will begin offering customers the ability to screen kinases using its internally developed microarray platform, according to a top official.

Steven Pelech, the firm's co-founder, president, and chief scientific officer, told BioArray News recently that the new kinase-inhibitor screening service will complement the firm's menu of Kinex antibody and reverse lysate microarrays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.